SAN FRANCISCO (Thomson Financial) - Repligen Corp. said Wednesday the U.S.
Food and Drug Administration has granted fast track designation to the
development program for RG1068, synthetic human secretin, to improve the
assessment of pancreatic duct structures by magnetic resonance imaging.
Repligen is currently conducting a Phase III clinical trial to evaluate the
use of RG1068.
Shares of Waltham, Mass.-based Repligen fell 13 cents to $5.38.
Gabriel Madway
gm
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|